Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ: AGIO) insider transactions

In the twelve months to 10 November 2026, executives and directors of Agios Pharmaceuticals reported 42 open-market sales of 160,154 shares ($5.0m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Agios Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
26 October 2026Gheuens SarahChief Medical OfficerOption exercise, 10b5-1 plan+7,866$25.0162,511Form 4
26 October 2026Gheuens SarahChief Medical OfficerOpen-market sale, 10b5-1 plan−7,866$37.6954,645Form 4
22 October 2026Gheuens SarahChief Medical OfficerOption exercise, 10b5-1 plan+500$25.0155,145Form 4
22 October 2026Gheuens SarahChief Medical OfficerOpen-market sale, 10b5-1 plan−500$37.5254,645Form 4
21 October 2026Gheuens SarahChief Medical OfficerOption exercise, 10b5-1 plan+1,489$25.0156,134Form 4
21 October 2026Gheuens SarahChief Medical OfficerOpen-market sale, 10b5-1 plan−1,489$37.5354,645Form 4
4 August 2026Gheuens SarahChief Medical OfficerOpen-market sale, 10b5-1 plan−30,000$30.4854,645Form 4
8 July 2026Backstrom Jay T.DirectorGrant or award+1,447—1,447Form 4
1 July 2026Gheuens SarahChief Medical OfficerOption exercise, 10b5-1 plan+8,375—88,652Form 4
1 July 2026Gheuens SarahChief Medical OfficerOpen-market sale, 10b5-1 plan−4,007$37.5684,645Form 4
18 June 2026Smith CynthiaDirectorOption exercise+2,816—15,230Form 4
18 June 2026Scadden DavidDirectorOption exercise+2,816—20,419Form 4
18 June 2026Owen Adams CatherineDirectorOption exercise+2,816—10,865Form 4
18 June 2026Ho MaykinDirectorOption exercise+2,816—19,848Form 4
18 June 2026Fouse Jacqualyn ADirectorOption exercise+2,816—154,156Form 4
18 June 2026Foster-Cheek Kaye IDirectorOption exercise+2,816—10,284Form 4
18 June 2026Capello Jeffrey DDirectorOption exercise+2,816—10,865Form 4
18 June 2026Ballal Rahul D.DirectorOption exercise+2,816—15,230Form 4
13 June 2026Capello Jeffrey DDirectorOption exercise+1,976—8,049Form 4
13 June 2026Owen Adams CatherineDirectorOption exercise+1,976—8,049Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Agios Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.